• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-X filed by Aurora Cannabis Inc.

    2/14/25 4:34:39 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ACB alert in real time by email
    F-X 1 d850650dfx.htm F-X F-X

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM F-X

     

     

    APPOINTMENT OF AGENT FOR SERVICE

    OF PROCESS AND UNDERTAKING

     

     

     

    A.   Name of issuer or person filing (“Filer”):    Aurora Cannabis Inc.

     

    B.  

    (1)   This is [check one]:

     

    ☒   an original filing for the Filer

     

    ☐   an amended filing for the Filer

     

    (2)   Check the following box if you are filing the Form F-X in paper in accordance with Regulation S-T Rule 101(b)(9) ☐

    C.   Identify the filing in conjunction with which this form is being filed:

     

      Name of Registrant:    Aurora Cannabis Inc.
      Form type:    F-10
      File Number (if known):    333-284958
      Filed by:    Aurora Cannabis Inc.
      Date Filed (if filed concurrently, so indicate):    February 14, 2025 (filed concurrently)
    D.  

    The Filer is incorporated or organized under the laws of British Columbia, Canada and has its principal place of business at:

     

    2207 90B Street SW

    Edmonton, Alberta, Canada

    T6X 1V8

    Telephone: 1 (855) 279-4652

    E.  

    The Filer designates and appoints Puglisi & Associates located at:

     

    850 Library Avenue

    Suite 204

    Newark, DE 19711

    Telephone: (302) 738-6680

     

    as the agent of the Filer upon whom may be served any process, pleadings, subpoenas, or other papers in:

     

    (a) any investigation or administrative proceeding conducted by the Commission; and

     

    (b) any civil suit or action brought against the Filer or to which the Filer has been joined as defendant or respondent, in any appropriate court in any place subject to the jurisdiction of any state or of the United States or of any of its territories or possessions or of the District of Columbia, where the investigation, proceeding or cause of action arises out of or relates to or concerns any offering made or purported to be made in connection with the securities registered or qualified by the Filer on Form F-10 on February 14, 2025 or any purchases or sales of any security in connection therewith. The Filer stipulates and agrees that any such civil suit or action or administrative proceeding may be commenced by the service of process upon, and that service of an administrative subpoena shall be effected by service upon such agent for service of process, and that the service as aforesaid shall be taken and held in all courts and administrative tribunals to be valid and binding as if personal service thereof had been made.

    F.  

    The Filer stipulates and agrees to appoint a successor agent for service of process and file an amended Form F-X if the Filer discharges the Agent or the Agent is unwilling or unable to accept service on behalf of the Filer at any time until six years have elapsed from the date the issuer of the securities to which this Form relates has ceased reporting under the Exchange Act.

     

    The Filer further undertakes to advise the Commission promptly of any change to the Agent’s name or address during the applicable period by amendment of this Form, referencing the file number of the relevant form in conjunction with which the amendment is being filed.

    G.   The Filer undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the Commission staff, and to furnish promptly, when requested to do so by the Commission staff, information relating to the Form F-10, the securities to which the Form F-10 relates and the transactions in such securities.

     

     

     


    The Filer certifies that it has duly caused this power of attorney, consent, stipulation and agreement to be signed on its behalf by the undersigned, thereunto duly authorized, this 14th day of February, 2025.

     

    Filer:     Aurora Cannabis Inc.
        By:   /s/ Miguel Martin
        Name:   Miguel Martin
        Title:   Chief Executive Officer and Executive Chairman


    This statement has been signed by the following person in the capacity and on the date indicated.

     

    Puglisi & Associates

    as Agent for Service of Process for

    Aurora Cannabis Inc.

    By:   /s/ Donald J. Puglisi
    Name:   Donald J. Puglisi
    Title:   Managing Director
    Dated:   February 14, 2025
    Get the next $ACB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACB

    DatePrice TargetRatingAnalyst
    12/11/2024Buy
    TD Cowen
    2/9/2024Hold → Buy
    Canaccord Genuity
    9/21/2022Sell → Hold
    Canaccord Genuity
    6/24/2022Neutral → Overweight
    Cantor Fitzgerald
    6/6/2022Sell → Hold
    Stifel
    11/10/2021$9.60 → $10.75Neutral
    Cantor Fitzgerald
    10/28/2021$9.50 → $9.60Neutral
    Cantor Fitzgerald
    10/5/2021$8.30 → $9.50Neutral
    Cantor Fitzgerald
    More analyst ratings

    $ACB
    Leadership Updates

    Live Leadership Updates

    See more
    • Rubicon Organics Announces Appointment of Glen Ibbott as Interim CFO

      VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics" or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Interim Chief Financial Officer. Janis Risbin, current CFO, will be stepping away from her full-time role effective today. She will remain in an advisory role over the next few months to ensure a smooth transition of responsibilities to Mr. Ibbott. "Glen's leadership at Aurora C

      5/15/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora CEO Miguel Martin takes on additional role as Executive Chairman of Board of Directors

      NASDAQ | TSX: ACB Outgoing Chairman Ron Funk appointed Lead Independent Director, as part of Board leadership transition EDMONTON, AB, Sept. 20, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced the appointments of CEO Miguel Martin to the additional role of Executive Chairman and outgoing Chairman Ron Funk as Lead Independent Director. Both appointments follow unanimous votes by Aurora's Board and are effective immediately. Mr. Martin has served as Chief Executiv

      9/20/24 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis Announces Results of 2024 Annual General and Special Meeting

      NASDAQ | TSX: ACB EDMONTON, AB, Aug. 12, 2024 /PRNewswire/ -  Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held Friday August 9, 2024 by virtual webcast. The total number of shares represented by shareholders present in person (virtually) and by proxy at the Meeting was 14,855,306, representing 27.23% of Aurora's issued and outstanding common shares as of the record date. All of

      8/12/24 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Financials

    Live finance-specific insights

    See more
    • Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2025 Investor Conference Call and File Related Year End Information

      NASDAQ | TSX: ACB EDMONTON, AB, June 3, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2025 on Wednesday, June 18, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2025 before the opening of markets that same day. Conference Call Details DATE: Wednesday, June 18, 2025

      6/3/25 4:15:00 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora to Participate in TD Cowen's 9th Annual Future of the Consumer Conference

      NASDAQ | TSX: ACB Canada's Largest Medical Cannabis Company to Discuss Key Trends, Market Opportunities and the Future of the Global Cannabis Industry EDMONTON, AB, May 27, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, will participate in TD Cowen's 9th Annual Future of the Consumer Conference in New York City, NY. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat and one-on-one meetings with investors on June 3, 2025, at 2:45pm EST. Conference Call Details DATE: Tues

      5/27/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis Announces Fiscal 2025 Third Quarter Results

      NASDAQ | TSX: ACB Reports Total Net Revenue1 of $88.2 Million, up 37% YoY, Including Record Net Revenue1 of $68.1 Million in Global Medical Cannabis, up 51% YoYGenerates Record Net Income of $31.2 Million, up 282% YoY, and Record Adjusted EBITDA1 of $23.1 Million, up 316% YoYAchieves Target of Positive Free Cash Flow1 in Q3, Generating $27.4 Million of Free Cash Flow1Maintains Strong Balance Sheet with $180 Million of Cash and Debt-Free Cannabis Business2EDMONTON, AB, Feb. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third qu

      2/5/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    SEC Filings

    See more
    • SEC Form 6-K filed by Aurora Cannabis Inc.

      6-K - AURORA CANNABIS INC (0001683541) (Filer)

      6/4/25 10:31:15 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Aurora Cannabis Inc.

      6-K - AURORA CANNABIS INC (0001683541) (Filer)

      5/27/25 6:49:58 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Aurora Cannabis Inc.

      6-K - AURORA CANNABIS INC (0001683541) (Filer)

      3/20/25 9:27:09 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Aurora Cannabis

      TD Cowen initiated coverage of Aurora Cannabis with a rating of Buy

      12/11/24 10:35:16 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Aurora Cannabis from Hold to Buy

      2/9/24 6:09:16 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Aurora Cannabis from Sell to Hold

      9/21/22 9:02:55 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aurora Expands Medical Cannabis Offerings in Australia with the Launch of IndiMed TEMPO 22

      NASDAQ | TSX: ACB  Canada's Largest Medical Cannabis Company Adds Two New Cultivars to Popular Brand Portfolio in the Australian Market EDMONTON, AB, June 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, has expanded their popular IndiMed brand with the launch of IndiMed TEMPO 22, available through the company's subsidiary, MedReleaf Australia. With the same consistent quality and reliable supply, this new 22% THC potency creates a greater range of treatment options available to prescribers. "Expanding our portfolio in the value segment in Australia reinforces our commitment to meet increasingly diversified pati

      6/5/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2025 Investor Conference Call and File Related Year End Information

      NASDAQ | TSX: ACB EDMONTON, AB, June 3, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2025 on Wednesday, June 18, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2025 before the opening of markets that same day. Conference Call Details DATE: Wednesday, June 18, 2025

      6/3/25 4:15:00 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora to Participate in TD Cowen's 9th Annual Future of the Consumer Conference

      NASDAQ | TSX: ACB Canada's Largest Medical Cannabis Company to Discuss Key Trends, Market Opportunities and the Future of the Global Cannabis Industry EDMONTON, AB, May 27, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, will participate in TD Cowen's 9th Annual Future of the Consumer Conference in New York City, NY. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat and one-on-one meetings with investors on June 3, 2025, at 2:45pm EST. Conference Call Details DATE: Tues

      5/27/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

      SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

      2/14/23 11:28:04 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Aurora Cannabis Inc.

      SC 13G - AURORA CANNABIS INC (0001683541) (Subject)

      6/1/22 10:14:29 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

      SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

      2/14/22 3:54:29 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care